Literature DB >> 19563866

Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.

Wayne Balkan1, Ariel F Martinez, Isabel Fernandez, Maria A Rodriguez, Manhui Pang, Bruce R Troen.   

Abstract

The receptor activator of NFkappaB ligand (RANKL) is a critical mediator of osteoclastogenesis and regulates cathepsin K (CTSK) expression, which is essential for normal bone resorption. RANKL acts, in part, via the Ca(2+)/calmodulin/calcineurin signaling pathway, which in turn, activates NFATc1 (nuclear factor of activated T-cells) and downstream gene expression. We investigated the signals and promoter elements that regulate CTSK gene expression in RAW 264.7 cells, which can be differentiated to osteoclasts by RANKL. Disrupting Ca(2+) signaling, by blocking Ca(2+) channels, thus inhibiting calcineurin or chelation of intracellular Ca(2+), prevented the stimulation of CTSK expression by RANKL. Both RANKL treatment and overexpression of NFATc1 dramatically enhanced CTSK promoter activity, but not in an identical manner. NFATc1 regulates CTSK promoter activity, but the motifs have not been explicitly identified. We found that as few as 238 bp of the CTSK promoter were sufficient to elicit a marked response to both RANKL and NFATc1, truncations of the CTSK promoter illustrated differences in regional responsiveness. Transfection analysis of CTSK promoter-luciferase plasmids revealed that NFATc1 binding sites at 85, 289 and 345 bp upstream of the transcriptional start site mediated responses to RANKL and NFATc1. Deletion of a 4-bp core element from the site at -85 bp dramatically reduced the response of the CTSK promoter to both RANKL and NFATc1, whereas a similar deletion at -345 bp decreased NFATc1- but not RANKL-mediated responses. Mutation of the site at -289 bp did not affect NFAT-mediated stimulation of CTSK on its own, but did decrease responsiveness in combination with either or both of the other two deletions. Electrophoretic mobility shift assays demonstrated NFATc1 binding to oligonucleotides containing the -85-bp and -345-bp sites, while chromatin immunoprecipitation assays demonstrated enhanced in situ binding by NFATc1 to two analogous sites in the mouse CTSK promoter in response to RANKL treatment. Therefore, proximal NFAT binding sites play a significant role in the NFATc1-mediated stimulation of CTSK gene expression by RANKL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563866     DOI: 10.1016/j.gene.2009.06.013

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  21 in total

Review 1.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

2.  Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.

Authors:  Nobunori Takahashi; Takayoshi Fujibayashi; Daihei Kida; Yuji Hirano; Takefumi Kato; Daizo Kato; Kiwamu Saito; Atsushi Kaneko; Yuichiro Yabe; Hideki Takagi; Takeshi Oguchi; Hiroyuki Miyake; Tsuyoshi Watanabe; Masatoshi Hayashi; Yasuhide Kanayama; Koji Funahashi; Masahiro Hanabayashi; Shinya Hirabara; Shuji Asai; Toki Takemoto; Kenya Terabe; Nobuyuki Asai; Yutaka Yoshioka; Naoki Ishiguro; Toshihisa Kojima
Journal:  Rheumatol Int       Date:  2015-05-20       Impact factor: 2.631

3.  Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm.

Authors:  Arend Jan Nieuwland; Vivianne Bc Kokje; Olivier H Koning; Jaap F Hamming; Karoly Szuhai; Frans H J Claas; Jan H N Lindeman
Journal:  Lab Invest       Date:  2016-05-30       Impact factor: 5.662

4.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

5.  Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Authors:  Cristiano A F Zerbini; Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

6.  SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.

Authors:  Yi Zhou; Aron Mohan; Douglas C Moore; Liangjun Lin; Frank Li Zhou; Jay Cao; Qian Wu; Yi-Xian Qin; Anthony M Reginato; Michael G Ehrlich; Wentian Yang
Journal:  FASEB J       Date:  2015-01-15       Impact factor: 5.191

7.  Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.

Authors:  Jason M God; Christine Cameron; Janette Figueroa; Shereen Amria; Azim Hossain; Bettina Kempkes; Georg W Bornkamm; Robert K Stuart; Janice S Blum; Azizul Haque
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

8.  Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.

Authors:  Wayne Balkan; María Rodríguez-Gonzalez; Manhui Pang; Isabel Fernandez; Bruce R Troen
Journal:  J Bone Miner Metab       Date:  2011-03-08       Impact factor: 2.626

9.  Fibrillin-1 directly regulates osteoclast formation and function by a dual mechanism.

Authors:  Kerstin Tiedemann; Iris Boraschi-Diaz; Irina Rajakumar; Jasvir Kaur; Peter Roughley; Dieter P Reinhardt; Svetlana V Komarova
Journal:  J Cell Sci       Date:  2013-09-15       Impact factor: 5.285

10.  Antiresorptive activity of bacillus-fermented antler extracts: inhibition of osteoclast differentiation.

Authors:  Sik-Won Choi; Seong-Hee Moon; Hye Jeong Yang; Dae Young Kwon; Young-Jin Son; Ri Yu; Young Su Kim; So I Kim; Eun Jeong Chae; Sang-Joon Park; Seong Hwan Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.